A thorough evaluation of each step of the #drugdevelopment process is the only way to be certain you’re free from nitrosamine contamination.

In its original advice to MAH’s, the European Medicines Agency warned manufacturers that it had identified 5 main root causes of formation and contamination. The risk from the raw materials, formation during the processing of the APIs, the use of certain solvents, reagents or catalysts, & indeed the use of recycled materials were featured as real risks.

By evaluating and then testing each individual material & step taken in the manufacturing process, you can correctly understand the influence of factors such as temperature change and solvent type used; each of which can have an impact and increase the amount of, or in some cases even cause, nitrosamines.  Only then you can be certain that the end product is safe and contamination free.

With the saga continuing to impact the pharma world, there has never been a more critical time to choose the correct partner.

Chartwell Actives LLC and QUINTA-ANALYTICA work together to offer a holistic approach to evaluating, performing risk-assessments, and running experimental testing for nitrosamines.

Additional News

  • 18 July 2023

    Challenges of a large-scale study of breast cancer

    Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.

  • 29 June 2023

    EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.

    After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.

  • 22 June 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency